Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity.

Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity.

Mostrar otras versiones (1)

Low plasma levels of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) are associated with decreased low-density lipoprotein (LDL) cholesterol and a reduced risk of cardiovascular disease. PCSK9 binds to the epidermal growth factor-like repeat A (EGFA) domain of LDL receptors (LDLR), very low-density...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rhogerry Deshycka, Valentino Sudaryo, Nai-Jia Huang, Yushu Xie, Liyan Y Smeding, Moon Kyung Choi, Hidde L Ploegh, Harvey F Lodish, Novalia Pishesha
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/578e74400dc64fdb8e36d78c1909d017
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares